Premium
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
Author(s) -
Lebwohl David,
Anak Özlem,
Sahmoud Tarek,
Klimovsky Judith,
Elmroth Ingrid,
Haas Tomas,
Posluszny Joseph,
Saletan Stephen,
Berg William
Publication year - 2013
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12122
Subject(s) - everolimus , discovery and development of mtor inhibitors , medicine , tuberous sclerosis , sirolimus , pi3k/akt/mtor pathway , cancer , oncology , neuroendocrine tumors , intensive care medicine , pathology , biochemistry , apoptosis , chemistry
Everolimus is a potent, oral inhibitor of the mammalian target of rapamycin (mTOR) that has been investigated in multiple clinical development programs since 1996. A unique collaboration between academic and pharmaceutical experts fostered research that progressed rapidly, with simultaneous indication findings across numerous tumor types. Initially developed for the prophylaxis of organ transplant rejection, everolimus has demonstrated efficacy and safety for the treatment of patients with various types of cancer (renal cell carcinoma, neuroendocrine tumors of pancreatic origin, and breast cancer) and for adult and pediatric patients with tuberous sclerosis complex. The FDA approval of everolimus for these diseases has addressed several unmet medical needs and is widely accepted by the medical community where treatment options may be limited. An extensive clinical development program is ongoing to establish the role of everolimus as monotherapy, or in combination with other agents, in the treatment of a broad spectrum of malignancies.